<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04308358</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-17T05:30:44+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms</title>
            <author role="aut">
              <persName>
                <forename type="first">Gurvan</forename>
                <surname>Hermange</surname>
              </persName>
              <idno type="halauthorid">2304140-0</idno>
              <affiliation ref="#struct-1042590"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Paul-Henry</forename>
                <surname>Cournède</surname>
              </persName>
              <email type="md5">7fbd834794a518970b717a9867dca40e</email>
              <email type="domain">centralesupelec.fr</email>
              <idno type="idhal" notation="string">paul-henry-cournede</idno>
              <idno type="idhal" notation="numeric">15896</idno>
              <idno type="halauthorid" notation="string">144626-15896</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-7679-6197</idno>
              <idno type="IDREF">https://www.idref.fr/145563073</idno>
              <affiliation ref="#struct-1042590"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Isabelle</forename>
                <surname>Plo</surname>
              </persName>
              <email type="md5">6cee02cd6f8983beae7c0db245702ccb</email>
              <email type="domain">gustaveroussy.fr</email>
              <idno type="idhal" notation="string">isabelle-plo</idno>
              <idno type="idhal" notation="numeric">760113</idno>
              <idno type="halauthorid" notation="string">338019-760113</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-5915-6910</idno>
              <idno type="IDREF">https://www.idref.fr/068888376</idno>
              <affiliation ref="#struct-156104"/>
              <affiliation ref="#struct-1049541"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Gurvan</forename>
                <surname>Hermange</surname>
              </persName>
              <email type="md5">9b827148148432cae200aee71a229c5e</email>
              <email type="domain">centralesupelec.fr</email>
            </editor>
            <funder ref="#projanr-54797"/>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2023-12-05 11:17:38</date>
              <date type="whenModified">2024-07-16 11:56:20</date>
              <date type="whenReleased">2023-12-07 15:22:46</date>
              <date type="whenProduced">2023-10-30</date>
              <date type="whenEndEmbargoed">2023-11-27</date>
              <ref type="file" target="https://centralesupelec.hal.science/hal-04308358v1/document">
                <date notBefore="2023-11-27"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://centralesupelec.hal.science/hal-04308358v1/file/optimizing_final.pdf" id="file-4308358-3768400">
                <date notBefore="2023-11-27"/>
              </ref>
              <ref type="annex" n="0" target="https://centralesupelec.hal.science/hal-04308358v1/file/optimizing_suppl.pdf" id="file-4308358-3768401">
                <date notBefore="2023-12-05"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="1104690">
                <persName>
                  <forename>Gurvan</forename>
                  <surname>Hermange</surname>
                </persName>
                <email type="md5">9b827148148432cae200aee71a229c5e</email>
                <email type="domain">centralesupelec.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04308358</idno>
            <idno type="halUri">https://centralesupelec.hal.science/hal-04308358</idno>
            <idno type="halBibtex">hermange:hal-04308358</idno>
            <idno type="halRefHtml">&lt;i&gt;Journal of Pharmacology and Experimental Therapeutics&lt;/i&gt;, 2023, 387 (1), pp.31-43. &lt;a target="_blank" href="https://dx.doi.org/10.1124/jpet.122.001561"&gt;&amp;#x27E8;10.1124/jpet.122.001561&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Journal of Pharmacology and Experimental Therapeutics, 2023, 387 (1), pp.31-43. &amp;#x27E8;10.1124/jpet.122.001561&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4308358-3768400"/><ref corresp="#file-4308358-3768401"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="FNCLCC" corresp="INSERM">UNICANCER</idno>
            <idno type="stamp" n="IGR" corresp="FNCLCC">Institut Gustave Roussy</idno>
            <idno type="stamp" n="CENTRALESUPELEC">Ecole CentraleSupélec</idno>
            <idno type="stamp" n="MICS">Mathématiques et Informatique pour la Complexité et les Systèmes</idno>
            <idno type="stamp" n="TDS-MACS">Réseau de recherche en Théorie des Systèmes Distribués, Modélisation, Analyse et Contrôle des Systèmes</idno>
            <idno type="stamp" n="UNIV-PARIS-SACLAY">Université Paris-Saclay</idno>
            <idno type="stamp" n="UNIVERSITE-PARIS-SACLAY" corresp="UNIV-PARIS-SACLAY">Université Paris-Saclay</idno>
            <idno type="stamp" n="ANR">ANR</idno>
            <idno type="stamp" n="GS-COMPUTER-SCIENCE">Graduate School Computer Science</idno>
            <idno type="stamp" n="HUB-IA">Hub Intelligence Artificielle de CentraleSupélec</idno>
            <idno type="stamp" n="CSHMYELO">Cellules souches hématopoïétiques et développement des hémopathies myéloïdes </idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Gurvan</forename>
                    <surname>Hermange</surname>
                  </persName>
                  <idno type="halauthorid">2304140-0</idno>
                  <affiliation ref="#struct-1042590"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Paul-Henry</forename>
                    <surname>Cournède</surname>
                  </persName>
                  <email type="md5">7fbd834794a518970b717a9867dca40e</email>
                  <email type="domain">centralesupelec.fr</email>
                  <idno type="idhal" notation="string">paul-henry-cournede</idno>
                  <idno type="idhal" notation="numeric">15896</idno>
                  <idno type="halauthorid" notation="string">144626-15896</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-7679-6197</idno>
                  <idno type="IDREF">https://www.idref.fr/145563073</idno>
                  <affiliation ref="#struct-1042590"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Isabelle</forename>
                    <surname>Plo</surname>
                  </persName>
                  <email type="md5">6cee02cd6f8983beae7c0db245702ccb</email>
                  <email type="domain">gustaveroussy.fr</email>
                  <idno type="idhal" notation="string">isabelle-plo</idno>
                  <idno type="idhal" notation="numeric">760113</idno>
                  <idno type="halauthorid" notation="string">338019-760113</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-5915-6910</idno>
                  <idno type="IDREF">https://www.idref.fr/068888376</idno>
                  <affiliation ref="#struct-156104"/>
                  <affiliation ref="#struct-1049541"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">15999</idno>
                <idno type="issn">0022-3565</idno>
                <idno type="eissn">1521-0103</idno>
                <title level="j">Journal of Pharmacology and Experimental Therapeutics</title>
                <imprint>
                  <publisher>American Society for Pharmacology and Experimental Therapeutics</publisher>
                  <biblScope unit="volume">387</biblScope>
                  <biblScope unit="issue">1</biblScope>
                  <biblScope unit="pp">31-43</biblScope>
                  <date type="datePub">2023-10-30</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1124/jpet.122.001561</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <classCode scheme="halDomain" n="info.info-bi">Computer Science [cs]/Bioinformatics [q-bio.QM]</classCode>
              <classCode scheme="halDomain" n="info.info-mo">Computer Science [cs]/Modeling and Simulation</classCode>
              <classCode scheme="halDomain" n="math.math-st">Mathematics [math]/Statistics [math.ST]</classCode>
              <classCode scheme="halDomain" n="sdv.sp.pharma">Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Myeloproliferative Neoplasms (MPNs) are hematological malignancies that result from acquired driver mutations in hematopoietic stem cells (HSCs), causing overproduction of blood cells and an increased risk of thrombo-hemorrhagic events. The most common MPN driver mutation affects the JAK2 gene (JAK2V617F). Interferon alpha (IFNα) is a promising treatment against MPNs by inducing a hematological response and molecular remission for some patients. Mathematical models have been proposed to describe how IFNα targets mutated HSCs, indicating that a minimal dose is necessary for long-term remission. This study aims to determine a personalized treatment strategy. First, we show the capacity of an existing model to predict cell dynamics for new patients from data that can be easily obtained in clinic. Then, we study different treatment scenarios in silico for three patients, considering potential IFNα dose-toxicity relations. We assess when the treatment should be interrupted, depending on the response, the patient's age, and the inferred development of the malignant clone without IFNα. We find that an optimal strategy would be to treat the patients with a constant dose so that the treatment could be interrupted as fast as possible. Higher doses result in earlier discontinuation but also higher toxicity. Without knowledge of the dose-toxicity relationship, trade-off strategies can be found for each patient. A compromise strategy is to treat patients with medium doses (60-120 µg/week) for 10-15 years. Altogether, this work demonstrates how a mathematical model calibrated from real data can help build a clinical decision-support tool to optimize long-term IFNα therapy for MPN patients.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-1042590" status="VALID">
          <idno type="IdRef">14797299X</idno>
          <idno type="RNSR">200615286U</idno>
          <idno type="ROR">https://ror.org/03q29s414</idno>
          <orgName>Mathématiques et Informatique pour la Complexité et les Systèmes</orgName>
          <orgName type="acronym">MICS</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>Plateau de Moulon 3 rue Joliot Curie 91192 GIF SUR YVETTE CEDEX</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://mics.centralesupelec.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-411575" type="direct"/>
            <relation active="#struct-419361" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-156104" status="VALID">
          <idno type="IdRef">026387433</idno>
          <idno type="ROR">https://ror.org/0321g0743</idno>
          <orgName>Institut Gustave Roussy</orgName>
          <orgName type="acronym">IGR</orgName>
          <desc>
            <address>
              <addrLine>114, rue Édouard-Vaillant 94805 Villejuif Cedex -France</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.gustaveroussy.fr/</ref>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-1049541" status="VALID">
          <orgName>Cellules souches hématopoïétiques et développement des hémopathies myéloïdes</orgName>
          <orgName type="acronym">CSHMyelo - U1287 Inserm</orgName>
          <desc>
            <address>
              <addrLine>Université Paris-Saclay, Institut Gustave Roussy,94805, Villejuif.</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.gustaveroussy.fr/fr/umr-1287</ref>
          </desc>
          <listRelation>
            <relation active="#struct-156104" type="direct"/>
            <relation name="U1287" active="#struct-303623" type="direct"/>
            <relation active="#struct-419361" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-411575" status="VALID">
          <idno type="IdRef">184443237</idno>
          <idno type="ROR">https://ror.org/019tcpt25</idno>
          <orgName>CentraleSupélec</orgName>
          <desc>
            <address>
              <addrLine>3, rue Joliot Curie,Plateau de Moulon,91192 GIF-SUR-YVETTE Cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.centralesupelec.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-419361" status="VALID">
          <idno type="IdRef">241345251</idno>
          <idno type="ROR">https://ror.org/03xjwb503</idno>
          <orgName>Université Paris-Saclay</orgName>
          <desc>
            <address>
              <addrLine>Bâtiment Bréguet, 3 Rue Joliot Curie 2e ét, 91190 Gif-sur-Yvette</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.universite-paris-saclay.fr/fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
      </listOrg>
      <listOrg type="projects">
        <org type="anrProject" xml:id="projanr-54797" status="VALID">
          <idno type="anr">ANR-18-IBHU-0002</idno>
          <orgName>PRISM</orgName>
          <desc>PRecISion Medicine Institute in oncology</desc>
          <date type="start">2018</date>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>